X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Novartis - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA NOVARTIS NATCO PHARMA/
NOVARTIS
 
P/E (TTM) x 27.5 377.8 7.3% View Chart
P/BV x 20.8 18.6 111.9% View Chart
Dividend Yield % 0.6 1.6 35.4%  

Financials

 NATCO PHARMA   NOVARTIS
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
NOVARTIS
Mar-16
NATCO PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs877982 89.3%   
Low Rs424556 76.1%   
Sales per share (Unadj.) Rs223.4252.9 88.3%  
Earnings per share (Unadj.) Rs31.162.1 50.0%  
Cash flow per share (Unadj.) Rs40.363.3 63.6%  
Dividends per share (Unadj.) Rs5.0010.00 50.0%  
Dividend yield (eoy) %0.81.3 59.1%  
Book value per share (Unadj.) Rs219.5363.6 60.4%  
Shares outstanding (eoy) m33.0731.96 103.5%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.93.0 95.7%   
Avg P/E ratio x20.912.4 169.1%  
P/CF ratio (eoy) x16.112.2 132.9%  
Price / Book Value ratio x3.02.1 140.1%  
Dividend payout %16.116.1 100.0%   
Avg Mkt Cap Rs m21,50424,580 87.5%   
No. of employees `000NA0.8 0.0%   
Total wages/salary Rs m1,1281,801 62.6%   
Avg. sales/employee Rs ThNM10,748.9-  
Avg. wages/employee Rs ThNM2,395.2-  
Avg. net profit/employee Rs ThNM2,641.1-  
INCOME DATA
Net Sales Rs m7,3898,083 91.4%  
Other income Rs m167829 20.1%   
Total revenues Rs m7,5568,913 84.8%   
Gross profit Rs m1,793234 765.7%  
Depreciation Rs m30437 829.4%   
Interest Rs m3662 20,344.4%   
Profit before tax Rs m1,2901,025 125.8%   
Minority Interest Rs m460-   
Prior Period Items Rs m017 0.0%   
Extraordinary Inc (Exp) Rs m01,696 0.0%   
Tax Rs m309752 41.1%   
Profit after tax Rs m1,0271,986 51.7%  
Gross profit margin %24.32.9 837.7%  
Effective tax rate %23.973.4 32.6%   
Net profit margin %13.924.6 56.6%  
BALANCE SHEET DATA
Current assets Rs m3,68112,678 29.0%   
Current liabilities Rs m3,1232,433 128.4%   
Net working cap to sales %7.6126.7 6.0%  
Current ratio x1.25.2 22.6%  
Inventory Days Days8933 273.7%  
Debtors Days Days5922 261.0%  
Net fixed assets Rs m7,68569 11,105.8%   
Share capital Rs m331160 206.9%   
"Free" reserves Rs m6,67011,460 58.2%   
Net worth Rs m7,25911,621 62.5%   
Long term debt Rs m9550-   
Total assets Rs m11,95714,400 83.0%  
Interest coverage x4.5570.5 0.8%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.60.6 110.1%   
Return on assets %11.713.8 84.4%  
Return on equity %14.217.1 82.8%  
Return on capital %20.723.6 87.9%  
Exports to sales %39.40.7 5,284.1%   
Imports to sales %5.718.6 30.7%   
Exports (fob) Rs m2,90860 4,830.2%   
Imports (cif) Rs m4211,503 28.0%   
Fx inflow Rs m3,445186 1,849.4%   
Fx outflow Rs m7031,821 38.6%   
Net fx Rs m2,743-1,635 -167.8%   
CASH FLOW
From Operations Rs m1,4402,531 56.9%  
From Investments Rs m-1,089-8,270 13.2%  
From Financial Activity Rs m-353-386 91.4%  
Net Cashflow Rs m-1-6,125 0.0%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 1.5 75.0 2.0%  
Indian inst/Mut Fund % 7.8 2.0 392.0%  
FIIs % 16.6 1.6 1,039.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 21.5 120.9%  
Shareholders   25,395 41,647 61.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   VENUS REMEDIES  ORCHID PHARMA LTD  SANOFI INDIA  J.B.CHEMICALS  SHASUN PHARMA  

Compare NATCO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Dull End to the Trading Day; Metal & Auto Stocks Fall(Closing)

Indian share markets continued to trade range-bound in the afternoon session amid mixed international markets. At the closing bell, the BSE Sensex closed higher by 27 points.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Of Falling Real Estate Prices, Dr Arvind Panagariya and the Art of Continuing to Suck Up(Vivek Kaul's Diary)

Nov 13, 2017

Dr Panagariya claims real estate prices have fallen 25 per cent post demonetisation; the official data doesn't show anything like that.

Your Last Chance to Trade ONLY the Best Stocks(Daily Profit Hunter)

Nov 11, 2017

Techno-Funda opportunities are knocking on your door. Are you ready to receive them?

When the Sherlock Holmes in Me Follows Super Investors...(The 5 Minute Wrapup)

Nov 11, 2017

This Super Investor has knack of spotting megatrends in India.

Why I am the Biggest India Equity Bull on Planet Earth!(The Honest Truth)

Nov 16, 2017

If you have a dream, dream big...about the level of BSE 30 index in 2050!

The Day Warren Buffett Lost All His Money(Smart Contrarian)

Nov 15, 2017

Buffett is still using the lessons he learnt that fateful day.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Nov 23, 2017 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS